Genesis Biopharma, Inc. Announces Completion of Merger With Lion Biotechnologies
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
LOS ANGELES--(BUSINESS WIRE)--Genesis Biopharma, Inc. (OTCBB: GNBP) today announced that it has completed a merger with Lion Biotechnologies, Inc., a privately held biotechnology company based in Los Angeles.
The merger will create a publicly traded biotechnology company, to be called Lion Biotechnologies, focused on developing T-cell based immunotherapy products for the treatment of cancer. Developed by Steven A. Rosenberg, chief of surgery at the National Cancer Institute (NCI), the company’s core technology has demonstrated robust efficacy in Phase II clinical trials, indicating 50-72% response rates in Stage IV metastatic melanoma.
Help employers find you! Check out all the jobs and post your resume.
LOS ANGELES--(BUSINESS WIRE)--Genesis Biopharma, Inc. (OTCBB: GNBP) today announced that it has completed a merger with Lion Biotechnologies, Inc., a privately held biotechnology company based in Los Angeles.
The merger will create a publicly traded biotechnology company, to be called Lion Biotechnologies, focused on developing T-cell based immunotherapy products for the treatment of cancer. Developed by Steven A. Rosenberg, chief of surgery at the National Cancer Institute (NCI), the company’s core technology has demonstrated robust efficacy in Phase II clinical trials, indicating 50-72% response rates in Stage IV metastatic melanoma.
Help employers find you! Check out all the jobs and post your resume.